Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

NCT04059679 is registered in ClinicalTrials.gov with LifeBridge Health as lead sponsor.

NCT NCT04059679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04059679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy
Lead sponsor
LifeBridge Health
Phase
Phase 4
Overall status
Unknown status
Start date
January 30, 2020
Completion date
August 31, 2021
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, peripheral artery disease